All In Biotech

Drug Trial Radar · NCT06711887

Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)

An Open-label Extension Study to Assess the Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Adult Participants With Lupus Nephritis Who Have Completed Study Treatment in the CVAY736K12301 Core Study (SIRIUS-LN Extension)

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

348

Planned (sponsor's estimate)

Start

May 19, 2025

Primary completion

Aug 1, 2035

Study completion Aug 1, 2035

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Dec 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this up to 6-year extension study is the evaluation of the efficacy and safety 1. after study treatment withdrawal in patients with lupus nephritis (LN) who achieved response (complete renal response \[CRR\] or partial renal response \[PRR\]) on double-blind treatment at the end of the SIRIUS-LN core study, and 2. of open-label ianalumab 300 mg treatment in patients who, at the end of the SIRIUS-LN core study, were either already receiving ianalumab open-label treatment or did not meet CRR/PRR criteria on double-blind treatment at the end of the SIRIUS-LN core study.

Conditions

  • Lupus Nephritis

Interventions

  • IanalumabDrug

    Ianalumab (VAY736) is a human monoclonal antibody (mAb) of the IgG1/κ-class, directed against B cells and binding to BAFF receptor (BAFF-R).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1: Time to renal flare, increase in immunosuppressive medication, or deathTime frame: Between Week 144E1 and EOS (up to Week 456)
  2. Cohort 2: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: From the start of treatment in the SIRIUS-LN core study to EOS (up to week 560) of the extension study

Locations

53 sites in 18 countries. Site status is shown where the registry gives one.

  • Circuit Clinical

    Orchard Park, New York · Recruiting

  • Novartis Investigative Site

    Vitória, Espírito Santo, Brazil · Recruiting

  • Novartis Investigative Site

    Salvador, Estado de Bahia, Brazil · Recruiting

  • Novartis Investigative Site

    Belo Horizonte, Minas Gerais, Brazil · Recruiting

  • Novartis Investigative Site

    Recife, Pernambuco, Brazil · Recruiting

  • Novartis Investigative Site

    Santo André, São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    Beijing, China · Active not recruiting

  • Novartis Investigative Site

    Chongqing, China · Recruiting

  • Novartis Investigative Site

    Guangzhou, China · Recruiting

  • Novartis Investigative Site

    Guangzhou, China · Recruiting

  • Novartis Investigative Site

    Shanghai, China · Recruiting

  • Novartis Investigative Site

    Shanghai, China · Recruiting

  • Novartis Investigative Site

    Guangzhou, Guangdong, China · Recruiting

  • Novartis Investigative Site

    Shantou, Guangdong, China · Active not recruiting

  • Novartis Investigative Site

    Shenzhen, Guangdong, China · Recruiting

  • Novartis Investigative Site

    Liuzhou, Guangxi, China · Recruiting

  • Novartis Investigative Site

    Wuhan, Hubei, China · Recruiting

  • Novartis Investigative Site

    Changchun, Jilin, China · Recruiting

  • Novartis Investigative Site

    Shenyang, Liaoning, China · Recruiting

  • Novartis Investigative Site

    Binzhou, Shandong, China · Recruiting

  • Novartis Investigative Site

    Ningbo, Zhejiang, China · Recruiting

  • Novartis Investigative Site

    Medellín, Antioquia, Colombia · Recruiting

  • Novartis Investigative Site

    Barranquilla, Atlántico, Colombia · Recruiting

  • Novartis Investigative Site

    Olomouc, Czechia · Active not recruiting

  • Novartis Investigative Site

    Prague, Czechia · Recruiting

  • Novartis Investigative Site

    Grenoble, France · Recruiting

  • Novartis Investigative Site

    Guatemala City, Guatemala · Recruiting

  • Novartis Investigative Site

    Guatemala City, Departamento de Guatemala, Guatemala · Recruiting

  • Novartis Investigative Site

    Quetzaltenango, Departamento de Quetzaltenango, Guatemala · Recruiting

  • Novartis Investigative Site

    Tuenmen, Hong Kong · Recruiting

  • Novartis Investigative Site

    Budapest, Hungary · Recruiting

  • Novartis Investigative Site

    Kuala Lumpur, Kuala Lumpur, Malaysia · Recruiting

  • Novartis Investigative Site

    Sibu, Sarawak, Malaysia · Recruiting

  • Novartis Investigative Site

    Oaxaca City, Mexico · Recruiting

  • Novartis Investigative Site

    Querétaro, Mexico · Recruiting

  • Novartis Investigative Site

    León, Guanajuato, Mexico · Recruiting

  • Novartis Investigative Site

    Monterrey, Nuevo León, Mexico · Recruiting

  • Novartis Investigative Site

    Bucharest, Romania · Recruiting

  • Novartis Investigative Site

    Oradea, Jud Bihor, Romania · Recruiting

  • Novartis Investigative Site

    Singapore, Singapore · Recruiting

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.